Stereotactic radiotherapy of an accurately determined substrate is effective in treating uncontrolled ventricular tachycardia
ID
Bron
Aandoening
Ventricular tachycardias
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
(1) Number of patients in whom the (presumed) clinical VT(s) causing the presenting symptoms can be eliminated (equals: partial success in RFCA studies) for the study period of one year (after 6 weeks blanking).
(2) Number of patients with the elimination of highly symptomatic VTs (e.g. pre-syncopal VT) or highly symptomatic ICD therapy (e.g. ICD shocks) for the study period of one year (after 6 weeks blanking).
(3) Reduction of any ICD treated VT episodes by ≥80% at one year after treatment compared to the year before treatment (including VTs during the 6 weeks blanking)
Achtergrond van het onderzoek
Background
Ventricular tachycardias (VT) are a medical emergency and require immediate termination. VT typically occur in patients with a myocardial scar from myocardial infarction or from non-ischemic cardiomyopathies. Despite escalated antiarrhythmic drug (AAD) therapy and advanced catheter ablation technology, up to 50% of patients will experience recurrent VTs. New drugs are not available and current catheter technologies have important and well-recognized limitations in particular to reach deep intramural arrhythmogenic substrates or areas protected by insulated fat or calcification. Despite the availability of state-of the art technology and highly experienced operators in tertiary referral centers catheter ablation acutely fails to eliminate the electrical storm causing VTs in 9-12% of the patients. Procedural failure has important prognostic implications during short-term follow-up: sudden death occurs in up to 40% within 3 months despite the ICD, and electrical storm, recurs in almost all. For these patients’ therapeutic options to eliminate the VT sources inaccessible by current catheter technologies are urgently needed.
Aim
Treatment of uncontrolled ventricular tachycardia, inaccessible by the current state of the art catheter ablation techniques by using single dose stereotactic radiotherapy of an accurately determined substrate
Doel van het onderzoek
Stereotactic radiotherapy of an accurately determined substrate is effective in treating uncontrolled ventricular tachycardia
Onderzoeksopzet
Patients will recive follow up at 2 weeks, 4 weeks, 12 weeks, 6 months and 12 months after treatment to assess for adverse cardiac effects
Onderzoeksproduct en/of interventie
Stereotactic radiotherapy
Algemeen / deelnemers
Wetenschappers
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
In order to be eligible to participate in this study, a subject must meet all of the following criteria:
- Age ≥18
- Implanted ICD
- Structural heart disease with myocardial scar
- World Health Organization (WHO) / Eastern Cooperative Oncology Group (ECOG) performance status grade 0-3 in the past 3 months, or grade 4 if related to the arrhythmic presentation (from fully active to capable of limited self-care, see below for full explanation)
- Presenting with at least one of the following
Within the past 3 months: electrical storm (defined as ≥3 ICD shocks within 24h)
Within the past 3 months: 3 or more episodes of highly symptomatic sustained VT (either requiring ICD shocks, or leading to (pre)syncope)
Recurrent VT (high VT burden) leading to progressive heart failure
Symptomatic, incessant VT not detected by the device or reinitiating after ICD therapy
Progressive heart failure and indication for LVAD, in whom recurrent VT preclude LVAD implantation
- Despite all of the following
Optimal medical treatment according to current guidelines
Failure of recommended antiarrhythmic drugs including failure of amiodarone
Failure of catheter ablation using the current state of the art catheter ablation techniques to modify the VT substrate
- Able and willing to undergo all necessary evaluations, treatment and follow-up for the study and of follow-up thereafter
- Informed consent
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
A potential subject who meets any of the following criteria will be excluded from participation in this study:
- Pregnancy
- Interstitial pulmonary disease
- Irreversible renal insufficiency with a glomerular filtration rate <30ml/min (not related to the high VT burden)
- Life expectancy <12 months in the absence of VT
- Refusal or inability to provide informed consent or to undergo all necessary evaluations, treatment and follow-up for the study
Opzet
Deelname
Voornemen beschikbaar stellen Individuele Patiënten Data (IPD)
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL7950 |
| CCMO | NL70844.058.19 |
| OMON | NL-OMON52679 |